Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Carcinosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Carcinosis. Displaying page 1 of 1.
    EudraCT Number: 2007-001185-32 Sponsor Protocol Number: 38/2007/O/Sper Start Date*: 2007-03-28
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Protocol for the experimental study about Peritonectomy (CCR) associated with Chemo-Hyperthermic intra-peritonel (CHIP) treatment for primary or secondary peritoneal neoplastic desease (Peritoneal ...
    Medical condition: Peritoneal Carcinosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002738-55 Sponsor Protocol Number: 69HCL16-0134 Start Date*: 2017-01-06
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis ( IPOXA )
    Medical condition: Patients with peritoneal carcinosis of colorectal origin and uncertain resectability with an indication for systemic chemotherapy compatible with the FOLFIRI + bevacizumab combination.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10052171 Peritoneal carcinoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002917-30 Sponsor Protocol Number: CARCINOSIS Start Date*: 2015-09-10
    Sponsor Name:Medical University of Vienna
    Full Title: Assessment of histopathological response to combination chemotherapy with Oxaliplatin, Irinotecan, Fluorouracil and Bevacizumab in patients with peritoneal metastasis from colorectal cancer (CARCIN...
    Medical condition: Patients with peritoneal carcinomatosis from colorectal cancer are treated with a combination chemotherapy (FOLFOXIRI+ Bevacizumab)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    20.0 100000016861 10034672 Peritoneal metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006175-20 Sponsor Protocol Number: ACCORD 15/0608 - PRODIGE 7 Start Date*: 2009-05-11
    Sponsor Name:FNCLCC
    Full Title: Essai de phase III évaluant la place de la ChimioHyperthermie IntraPéritonéale per opératoire (CHIP) après résection maximale d'une carcinose péritonéale d'origine colorectale associée à une chimi...
    Medical condition: Notre étude multicentrique de phase III a donc pour objet de définir véritablement la place de la chimiohyperthermie intra-péritonéale en la randomisant chez ces patients ayant pu bénéficier d’une ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000126-31 Sponsor Protocol Number: 1401 Start Date*: 2006-06-24
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: A phase II trial of carboplatin and paclitaxel compared with carboplatin or gemcitabine paclitaxel "induction" followed by carboplatin/paclitaxel/gemcitabine in patients with suboptimally resected ...
    Medical condition: Epithelial ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033163 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002683-31 Sponsor Protocol Number: TUD-ALPINE-077 Start Date*: 2021-06-24
    Sponsor Name:Technische Universität Dresden
    Full Title: A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung
    Medical condition: locally advanced or metastatic large-cell neuroendocrine carcinoma of the lung (LCNEC) not eligible for curative treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078184 Neuroendocrine tumor of the lung metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078175 Neuroendocrine tumour of the lung metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014476-21 Sponsor Protocol Number: CONKO-007 Start Date*: 2013-02-22
    Sponsor Name:Dekan of the Medical Faculty of the University Erlangen-Nuremberg; Prof. Dr. med. Markus F. Neurath
    Full Title: Chemoradiation following induction chemotherapy in locally advanced, unresectable pancreatic cancer -a randomised phase 3 trial: Chemoradiation following induction chemotherapy compared with chemo...
    Medical condition: Locally advanced non resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000004-33 Sponsor Protocol Number: IPR/18 Start Date*: 2008-10-13
    Sponsor Name:MOLMED
    Full Title: NGR012: A phase II study of NGR-hTNF administered in combination with doxorubicin every 3 weeks in patients affected by advanced or metastatic ovarian cancer
    Medical condition: Patients affected by advanced or metastatic ovarian cancer previously treated with platinum regimens (cis or carboplatin) plus paclitaxel
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000765-12 Sponsor Protocol Number: MICORYX Start Date*: 2011-08-22
    Sponsor Name:Oryx GmbH & Co. KG
    Full Title: Phase I/IIa study of immunization with frameshift peptides administered with Montanide ISA-51 VG in patients with advanced MSI-H colorectal cancer
    Medical condition: advanced MSI-H colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004405-25 Sponsor Protocol Number: HIPEC_Stomach Start Date*: 2012-03-01
    Sponsor Name:University Hospital Tübingen
    Full Title: Study for prevention of peritoneal carcinomatosis in patients with stomach cancer
    Medical condition: Reducing the risk of peritoneal carcinomatosis in patients with stomach cancer with following treatment: gastrectomy incl. HIPEC vs. gastrectomy excl. HIPEC
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068069 Peritoneal carcinomatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002687-65 Sponsor Protocol Number: 2317 Start Date*: 2019-04-18
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: The NUVOLA TRIAL: Neoadjuvant chemoteraphy in Unresectable oVarian cancer with OLAparib and weekly carboplatin plus paclitaxel. A phase II open-label multi-centre study.
    Medical condition: ADVANCED OVARIAN CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054913 Serous cystadenocarcinoma ovary PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014725-16 Sponsor Protocol Number: AIO-SUP-0108 Start Date*: 2010-01-14
    Sponsor Name:AIO Studien gGmbH
    Full Title: Double-blind, placebo-controlled, randomized phase II-study investigating the efficacy of Bevacizumab for symptom control in patients with malignant ascites due to advanced-stage gastrointestinal c...
    Medical condition: patients with malignant ascites due to advanced-stage gastro-intestinal cancers
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015362 Esophageal cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049010 Carcinoma hepatocellular LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025538 Malignant ascites PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 14:50:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA